Anti-Envelope protein [ZKA64]

Absolute Antibody

Anti-Envelope protein [ZKA64]

9

ZKA64 binds specifically to the EDIII domain of the ZIKV envelope (E) protein. It does not cross-react with DENV E protein. Flavivirus E proteins mediate fusion, with EDIII being specifically invovled in binding to cellular receptors. The ZIKV E protein h

ZKA64 is able to neutralize ZIKV with an IC50 of ~93 ng/ml. This antibody also enhances ZIKV infection in non-permissive K562 cells at a broad range of concentrations (but not above 1 microg/ml). The LALA format of ZKA64 (an Fc mutant variant that does not bind to Fc gamma receptors and only weakly to complement - similar to Absolute Antibodys Fc Silent™ format) is able to block enhancement of ZIKV infection by ZIKV-immune plasma from convalescent patients in K652 cell by the ADE (antibody-dependent enhancement) effect - this is due to the capacity of ZKA64 to out-compete serum enhancing antibodies and to neutralize ZIKV once internalized into endosomes. ZKA64-LALA is able to completely protect A129 mice from death and body weight-loss when administered with a lethal dose of ZIKV. Neutralization of ZIKV infection can be measured using a micro-neutralization FC-based assay, and binding/specificity to E protein can be studied by ELISA. Paul et al. (2016, PMID: 28090318) used the mouse IgG2a version of this antibody (Ab00779-2.0) positive control for antibody-mediated virus neutralization.

Flow Cytometry, ELISA, Neutralisation/Blocking, Other Application

Research Use Only

Monoclonal

ZKA64

Mouse

IgG2a

Envelope protein

This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Virus

-20°C,2°C to 8°C

12352203